Quadrivalent meningococcal conjugate vaccines
| Autor: | David Pace, Andrew J. Pollard, Nancy E. Messonier |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Population
Meningococcal Vaccines Meningococcal vaccine Neisseria meningitidis Serogroup C Meningitis Meningococcal Neisseria meningitidis Serogroup B Meningococcal disease medicine.disease_cause Microbiology Neisseria meningitidis Serogroup W-135 Neisseria meningitidis Serogroup A Sepsis Medicine Humans Meningitis education education.field_of_study Vaccines Conjugate General Veterinary General Immunology and Microbiology biology business.industry Neisseria meningitidis Public Health Environmental and Occupational Health Paediatrics biology.organism_classification medicine.disease bacterial infections and mycoses Virology United States Vaccination Vaccinology Infectious Diseases Immunization Molecular Medicine Neisseriaceae business |
| Zdroj: | Vaccine. 27(SUPPL. 2) |
| ISSN: | 1873-2518 0264-410X |
| Popis: | Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect